INSMED INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INSMED INC (INSM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $41.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $41.25M, a 4.01% decline year-over-year.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $45.75M, a 16.54% increase year-over-year.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $39.04M, a 47.02% increase year-over-year.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $31.43M, a 23.05% increase year-over-year.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $152.71M, a 57.70% increase from fiscal 2024.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $96.83M, a 29.50% increase from fiscal 2023.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $74.78M, a 29.63% increase from fiscal 2022.
- INSMED INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $57.69M, a 25.35% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $41.25M 10-Q · filed 2026-08-06 | $87.01M 10-Q · filed 2026-08-06 | $126.05M derived: sum of 3 quarters · filed 2026-08-06 | $157.48M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $45.75M 10-Q · filed 2026-05-07 | $84.79M derived: sum of 2 quarters · filed 2026-05-07 | $116.23M derived: sum of 3 quarters · filed 2026-05-07 | $159.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $39.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $70.47M derived: sum of 2 quarters · filed 2026-02-19 | $113.45M derived: sum of 3 quarters · filed 2026-08-06 | $152.71M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $31.43M 10-Q · filed 2025-10-30 | $74.41M derived: sum of 2 quarters · filed 2026-08-06 | $113.67M 10-Q · filed 2025-10-30 | $140.22M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $42.98M 10-Q · filed 2026-08-06 | $82.24M 10-Q · filed 2026-08-06 | $108.79M derived: sum of 3 quarters · filed 2026-08-06 | $134.34M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $39.26M 10-Q · filed 2026-05-07 | $65.82M derived: sum of 2 quarters · filed 2026-05-07 | $91.36M derived: sum of 3 quarters · filed 2026-05-07 | $114.65M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $26.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $52.10M derived: sum of 2 quarters · filed 2026-02-19 | $75.39M derived: sum of 3 quarters · filed 2026-02-19 | $96.83M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $25.55M 10-Q · filed 2025-10-30 | $48.83M derived: sum of 2 quarters · filed 2025-10-30 | $70.28M 10-Q · filed 2025-10-30 | $90.26M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-06-30 | $23.29M 10-Q · filed 2025-08-07 | $44.74M 10-Q · filed 2025-08-07 | $64.72M derived: sum of 3 quarters · filed 2026-02-19 | $84.71M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-03-31 | $21.45M 10-Q · filed 2025-05-08 | $41.43M derived: sum of 2 quarters · filed 2026-02-19 | $61.43M derived: sum of 3 quarters · filed 2026-02-19 | $79.78M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2023-12-31 | $19.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $39.98M derived: sum of 2 quarters · filed 2026-02-19 | $58.34M derived: sum of 3 quarters · filed 2026-02-19 | $74.78M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $19.99M 10-Q · filed 2024-10-31 | $38.35M derived: sum of 2 quarters · filed 2024-10-31 | $54.80M 10-Q · filed 2024-10-31 | $69.75M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-06-30 | $18.36M 10-Q · filed 2024-08-08 | $34.80M 10-Q · filed 2024-08-08 | $49.75M derived: sum of 3 quarters · filed 2025-02-20 | $65.41M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-03-31 | $16.44M 10-Q · filed 2024-05-09 | $31.39M derived: sum of 2 quarters · filed 2025-02-20 | $47.05M derived: sum of 3 quarters · filed 2025-02-20 | $61.31M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2022-12-31 | $14.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $30.60M derived: sum of 2 quarters · filed 2025-02-20 | $44.86M derived: sum of 3 quarters · filed 2025-02-20 | $57.69M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $15.65M 10-Q · filed 2023-10-26 | $29.91M derived: sum of 2 quarters · filed 2023-10-26 | $42.74M 10-Q · filed 2023-10-26 | $54.26M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $14.26M 10-Q · filed 2023-08-03 | $27.08M 10-Q · filed 2023-08-03 | $38.60M derived: sum of 3 quarters · filed 2024-02-22 | $50.83M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $12.82M 10-Q · filed 2023-05-04 | $24.34M derived: sum of 2 quarters · filed 2024-02-22 | $36.57M derived: sum of 3 quarters · filed 2024-02-22 | $48.31M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $11.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $23.75M derived: sum of 2 quarters · filed 2024-02-22 | $35.49M derived: sum of 3 quarters · filed 2024-02-22 | $46.02M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $12.23M 10-Q · filed 2022-10-27 | $23.97M derived: sum of 2 quarters · filed 2022-10-27 | $34.50M 10-Q · filed 2022-10-27 | $43.28M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $11.73M 10-Q · filed 2022-08-04 | $22.27M 10-Q · filed 2022-08-04 | $31.05M derived: sum of 3 quarters · filed 2023-02-23 | $39.96M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $10.54M 10-Q · filed 2022-05-05 | $19.31M derived: sum of 2 quarters · filed 2023-02-23 | $28.22M derived: sum of 3 quarters · filed 2023-02-23 | $37.69M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $8.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $17.69M derived: sum of 2 quarters · filed 2023-02-23 | $27.16M derived: sum of 3 quarters · filed 2023-02-23 | $36.16M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $8.91M 10-Q · filed 2021-10-28 | $18.38M derived: sum of 2 quarters · filed 2021-10-28 | $27.38M 10-Q · filed 2021-10-28 | $33.27M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-06-30 | $9.47M 10-Q · filed 2021-08-05 | $18.47M 10-Q · filed 2021-08-05 | $24.36M derived: sum of 3 quarters · filed 2022-02-17 | $31.15M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2020-03-31 | $9.00M 10-Q · filed 2021-05-06 | $14.89M derived: sum of 2 quarters · filed 2022-02-17 | $21.68M derived: sum of 3 quarters · filed 2022-02-17 | $29.04M derived: sum of 4 quarters · filed 2022-02-17 | |
| 2019-12-31 | $5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $12.68M derived: sum of 2 quarters · filed 2022-02-17 | $20.04M derived: sum of 3 quarters · filed 2022-02-17 | $26.97M 10-K · filed 2022-02-17 | |
| 2019-09-30 | $6.79M 10-Q · filed 2020-10-29 | $14.15M derived: sum of 2 quarters · filed 2020-10-29 | $21.08M 10-Q · filed 2020-10-29 | $27.12M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $7.35M 10-Q · filed 2020-08-06 | $14.29M 10-Q · filed 2020-08-06 | $20.32M derived: sum of 3 quarters · filed 2021-02-25 | $28.23M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $6.94M 10-Q · filed 2020-04-30 | $12.97M derived: sum of 2 quarters · filed 2021-02-25 | $20.87M derived: sum of 3 quarters · filed 2021-02-25 | $27.50M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $6.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $13.94M derived: sum of 2 quarters · filed 2021-02-25 | $20.57M derived: sum of 3 quarters · filed 2021-02-25 | $26.24M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $7.90M 10-Q · filed 2019-10-30 | $14.53M derived: sum of 2 quarters · filed 2019-10-30 | $20.20M 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $6.63M 10-Q · filed 2019-08-01 | $12.30M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $5.67M 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $18.07M 10-K · filed 2020-02-25 | ||||
| 2016-12-31 | $18.04M 10-K · filed 2019-02-22 | ||||
| 2015-12-31 | $15.59M 10-K · filed 2018-02-23 | ||||
| 2014-12-31 | $11.33M 10-K · filed 2017-02-23 | ||||
| 2013-12-31 | $6.50M 10-K · filed 2016-02-25 | ||||
| 2012-12-31 | $1.78M 10-K · filed 2015-02-27 | $2.42M 10-K · filed 2013-03-18 | |||
| 2011-12-31 | $1.60M 10-K · filed 2014-03-06 | ||||
| 2010-12-31 | $366.00K 10-K · filed 2013-03-18 | ||||
| 2009-12-31 | $1.15M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |